Durvalumab, a fully human IgG1 antibody, and atezolizumab, a humanized IgG1 antibody, are currently the most relevant anti-PD-L1 agents investigated in the field of HCC [73]; however, recently, avelumab, another IgG1 human antibody, has also demonstrated encouraging results in clinical trials with HCC patients [76]. This evidence concerns the gene CD274 and hepatocellular carcinoma.